Syros Pharmaceuticals Announces New Publication Highlighting the Strong Potential of CDK7 Inhibition in Difficult-to-Treat Cancer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals, the industry pioneer in gene control, announced
today the publication of a new study co-authored by Jean Zhao, PhD of
the Dana-Farber Cancer Institute, and Syros scientific co-founders
Nathanael Gray, PhD, and Richard Young, PhD, that demonstrates the
central role played by cyclin-dependent kinase 7 (CDK 7) in the growth
of a highly aggressive form of breast cancer, and the strong potential
of selective inhibition of CDK7 as a novel treatment strategy. The
findings were published in the Sept 24 issue of Cell.

Triple-negative breast cancer (TNBC), as with many other
difficult-to-treat cancers, is characterized by a high degree of genetic
complexity that has made it out of reach for targeted therapies. In the
absence of a clear genetic target, researchers examined whether the
disease’s known dependence on the transcription of certain genes might
open a new avenue for drug development.

The Cell paper concluded that TNBC is dependent on the activity
of CDK7, a gene regulator that has emerged as a unique dependency in
some cancers. After confirming the selective role of CDK7 in TNBC, the
authors conducted a series of experiments that demonstrated the strong
potential of CDK7 inhibition to reduce tumor cell proliferation and
induce cancer cell death in animal models.

“These findings are an important validation of the central role of CDK7
in the survival and proliferation of cancer cells in triple negative
breast cancer and other difficult-to-treat forms of cancer,” said Eric
Olson, Chief Scientific Officer of Syros Pharmaceuticals. “We are making
strong progress in advancing our CDK7 inhibitor into the clinic. This
paper supports the broad potential of this program in addressing a range
of cancer types fueled by a strong dependence on gene transcription.”

Syros Pharmaceuticals has exclusively licensed CDK7 inhibitor
intellectual property from the Dana-Farber Cancer Institute. The company
is in late preclinical development of a CDK7 inhibitor for cancers with
transcriptional dependency.

About Syros Pharmaceuticals

Syros Pharmaceuticals is a therapeutics company harnessing breakthroughs
in gene control to revolutionize the treatment of cancer and other
diseases. Syros’ proprietary platform identifies the master switches for
disease genes, opening a whole new approach to novel therapeutics and
biomarkers. The Company’s founders are pioneers in gene control research
and translation. Co-founded by Flagship Ventures and ARCH Venture
Partners, Syros Pharmaceuticals is located in Cambridge, Mass. For more
information, visit


Media Contact:
Ten Bridge Communications, Inc.
Quinn, 781-475-7974

Stern Investor Relations, Inc.
Jesse Baumgartner,